Misconceptions Drive COVID-19 Vaccine Hesistancy in Individuals with Inflammatory Bowel Disease

Table 1

Respondent characteristics.

Survey Items	No. (percentage)
1. IBD diagnosis
Crohn’s disease	262 (59.4%)
Ulcerative colitis	161 (36.5%)
Indeterminate colitis	18 (4.1%)
2. Age group
16–30	90 (20.4%)
31–59	291 (66.0%)
60+	59 (13.4%)
3. Gender
Male	98 (22.2%)
Female	337 (76.4%)
4. Location of IBD care
Public hospital	192 (43.5%)
Private gastroenterologist	225 (51.2%)
General practitioner	23 (5.2%)
5. Highest level of education
High school	102(23.1%)
TAFE	91 (20.6%)
University	248 (56.2%)
6. Employment status
Student	27 (6.1%)
Employed	313 (71.0%)
Unemployed	99 (22.4%)
7. Current IBD medications
Mesalazine or sulfasalazine	178 (40.1%)
Methotrexate	34 (7.7%)
Azathioprine or mercaptopurine	161 (36.5%)
Anti-TNF	159 (36.1%)
Ustekinumab	34 (7.8%)
Vedolizumab	54 (12.2%)
Tofacitinib	3 (0.7%)
Prednisone or oral budesonide	41 (12.3%)
8. Vaccine obtained
Pfizer BNT162b2	273 (61.9%)
Astra Zeneca ChAdOx1 nCoV-1	133 (30.2%)
Moderna mRNA-1273	5 (1.1%)
9. Factors contributing to vaccine hesitancy amongst those not yet vaccinated
Unable to schedule vaccine appointment	1 (3%)
Concern about safety of vaccine	19 (63%)
Concern about IBD flaring with vaccination	20 (66%)
Waiting for advice from doctors	4 (13%)
Concern about how quickly vaccines were developed	17 (56%)
Do not believe in efficacy of vaccination	6 (20%)